Safety and efficacy of SARS-CoV-2 vaccination in patients with immune thrombocytopenia: A two-centre review

Sara Stefani*, Noora Buti, Alice C.J. Hart, Deena Paul, Naghma Rizvi, Vashti Ragoonanan, Camelia Vladescu, Richard Szydlo, Christine Ademokun, A. J.Gerard Jansen, Nichola Cooper

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

9 Downloads (Pure)

Abstract

Multiple studies have reported immune thrombocytopenia (ITP) relapse following SARS-CoV-2 vaccination, however baseline ITP relapse rate and antibody response to vaccination are not known. Patients with ITP who received at least one of the first three SARS-CoV-2 vaccination doses were included in the study. One hundred and twenty-four patients met the inclusion criteria. Relapse rate was 4.2% following a first vaccine dose, 9.1% after a second and 2.9% after a third; baseline relapse rate was 7.6%. Ninety-four per cent of patients who received three vaccine doses developed a clinical antibody response. SARS-CoV-2 vaccination appears to be safe and effective in patients with ITP.

Original languageEnglish
Pages (from-to)324-328
Number of pages5
JournalBritish Journal of Haematology
Volume204
Issue number1
Early online date27 Nov 2023
DOIs
Publication statusPublished - Jan 2024

Bibliographical note

Publisher Copyright:
© 2023 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.

Fingerprint

Dive into the research topics of 'Safety and efficacy of SARS-CoV-2 vaccination in patients with immune thrombocytopenia: A two-centre review'. Together they form a unique fingerprint.

Cite this